Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

FDA places clinical hold on phase IIb study of Flexion's FX-006 for knee osteoarthritis

Sep. 18, 2014

GSK exercises option to novel muscle disease target discovered by Five Prime

Sep. 17, 2014

Lysophospholipid S1P1 receptor modulators disclosed in Allergan patent

Sep. 17, 2014

Phase II trial of myostatin-targeted MAb LY-2495655 meets primary objective

Sep. 15, 2014

Invion reports data from first two dose cohorts in phase I/II trial of INV-103 in SLE

Sep. 10, 2014

RoActemra receives E.U. approval for patients with early rheumatoid arthritis

Sep. 9, 2014

Aesculap Biologics confirms first human implantation of Novocart 3D

Sep. 8, 2014

New ROR gamma modulators reported by Aurigene

Sep. 5, 2014

BMS returns clazakizumab rights to Alder BioPharmaceuticals

Sep. 4, 2014

Lilly patents new EP4 receptor antagonists

Sep. 4, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.